Skip to main content
TipRanks
Go Ultimate75% OFF

SI-Bone (SIBN) AI Stock Analysis

191 Followers
SIBN

SI-Bone

(NASDAQ:SIBN)

Select Model
Rating:70Outperform
Price Target:$26.00â–²(10.45% Upside)
Action:upgraded
Date:11/04/26

The score is driven primarily by improving (but still not fully profitable) financial performance and a strongly positive earnings call with reaffirmed guidance and better operating leverage, supported by bullish technical trends. Valuation remains a meaningful constraint due to ongoing net losses and a negative P/E.

Positive Factors
Procedure and Physician GrowthRising procedure volume, physician adoption and a larger commercial network expand the installed base that can generate recurring procedure-linked implant sales. This broadens reach beyond a small specialist group and supports durable utilization growth as training and account coverage deepen.
Negative Factors
Continued UnprofitabilitySI-BONE remains unprofitable despite materially narrower losses, so revenue growth has not yet translated into durable earnings. Continued operating losses can constrain strategic flexibility and leave the business dependent on further scale, execution and cost discipline before becoming self-sustaining.

SI-Bone (SIBN) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%30%40%SIBN+20.72%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.06B
Dividend Yield
―
Average Volume (3M)
713.88K
Price to Earnings (P/E)
-76.0
Beta (1Y)
0.47
Revenue Growth
13.99%
EPS Growth
39.54%
Country
US
Employees
376
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

SI-Bone Business Overview & Revenue Model

Company Description

SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its fl...

How the Company Makes Money

SI-Bone primarily makes money by selling its SI joint fusion implant systems and associated surgical instruments used in procedures performed in hospitals and ambulatory surgery centers. Revenue is generated largely from product sales per procedure (...

SI-Bone Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:16.42%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentPositive

The call was strongly positive. Highlights significantly outweighed the lowlights, with approximately 15% worldwide revenue growth, 20% U.S. procedure-volume growth, 32.4% adjusted EBITDA growth, stronger operating cash flow, reaffirmed revenue guidance and strong early Onyx demand. The main challenges were lower ASP from mix, the continued net loss, expected modest gross margin pressure in 2027 and the need for additional clinical data and finalized reimbursement decisions.

Positive Updates

Worldwide Revenue Growth
Third-quarter worldwide revenue grew approximately 15% to $55.7 million, or 14.5% growth according to the detailed financial results.

Negative Updates

Lower Average Selling Price
U.S. revenue growth was partially offset by lower average selling price. Management attributed the pressure to procedure mix, including more two-implant Granite cases, and increased INTRA adoption in ASC and office-based settings that typically carry lower ASP.

Company Guidance

SI-BONE reaffirmed 2026 worldwide revenue guidance of $231 million to $233 million and gross margin expectations at 79%, while now expecting operating expenses to grow 10.5% versus its prior expectation of 12%; the midpoint of annual worldwide revenue guidance implies over 20% year-over-year revenue growth in the fourth quarter, with Onyx expected to make a modest contribution in the fourth quarter and full launch expected in January, and the company is targeting to exit 2026 with nearly 100 territories. Long term, operating leverage is expected to be 1.25x revenue growth to OpEx growth on the low end and as high as 1.75x over the long term, with the midpoint of the leverage being around 1.4x, 1.5x, while gross margin is expected to be in sort of that 78% area as you go beyond 2027; if approved, Onyx NTAP would take effect on October 1, 2027.

SI-Bone Financial Statement Overview

Summary

Financials show clear improvement but not full durability yet: revenue scaled materially over multiple years and losses have narrowed significantly, with operating cash flow turning positive in TTM. Offsetting this, the company remains net-loss and operating-loss making, free cash flow is still negative, and the most recent TTM revenue growth decelerated sharply.

Income Statement

62Positive

Balance Sheet

68Positive

Cash Flow

48Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue220.65M200.93M167.18M138.89M106.41M90.15M
Gross Profit175.19M159.88M132.12M109.42M90.70M79.72M
EBITDA-3.91M-10.91M-23.09M-34.45M-54.98M-50.97M
Net Income-13.69M-18.91M-30.91M-43.34M-61.26M-56.57M
Balance Sheet
Total Assets256.77M238.56M230.44M230.43M157.55M190.51M
Cash, Cash Equivalents and Short-Term Investments146.26M147.82M150.04M166.02M97.29M146.98M
Total Debt42.80M1.12M37.48M38.99M39.43M40.48M
Total Liabilities72.09M61.02M63.47M61.05M59.25M56.09M
Stockholders Equity184.68M177.53M166.96M169.38M98.30M134.42M
Cash Flow
Free Cash Flow-4.19M-9.09M-22.92M-26.51M-51.16M-45.92M
Operating Cash Flow6.08M-675.00K-12.43M-18.71M-41.66M-39.53M
Investing Cash Flow-24.00K4.16M12.62M-59.80M-2.81M51.58M
Financing Cash Flow3.04M3.38M1.96M90.93M2.20M-1.71M

SI-Bone Technical Analysis

Technical Analysis SentimentPositive
Last Price23.54

Price Trends

50DMA20.67Positive
100DMA19.42Positive
200DMA16.86Positive

Market Momentum

MACD0.95Positive
RSI56.64Neutral
STOCH15.44Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIBN, the sentiment is Positive. The current price of 23.54 is above the 20-day moving average (MA) of 23.10, above the 50-day MA of 20.67, and above the 200-day MA of 16.86, indicating a bullish trend. The MACD of 0.95 indicates Positive momentum. The RSI at 56.64 is Neutral, neither overbought nor oversold. The STOCH value of 15.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SIBN.

SI-Bone Risk Analysis

SI-Bone disclosed 61 risk factors in its most recent earnings report. SI-Bone reported the most risks in the "Production" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

3 New Risks
1.If our information technology systems or those third parties with whom we work or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business, impairment of our results of operations, reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.Q4, 2024
2.We have incorporated and continue to work to further incorporate artificial intelligence into our operations. Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business.Q4, 2024
3.Uncertainty in the coverage and reimbursement environment may decrease demand for our products and adversely affect our business.Q4, 2024

SI-Bone Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SIBN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GMEDGMED73Outperform$9.27B17.0411.82%―13.35%32.22%
SIBNSIBN70Outperform$1.04B-75.98-7.57%―13.99%39.54%
ZBHZBH69Neutral$19.32B26.026.05%0.93%6.98%-2.22%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ATECATEC50Neutral$1.10B-12.61-547.17%―15.34%46.31%
OFIXOFIX44Neutral$269.42M-5.92-10.32%―2.12%63.59%
XTNTXTNT39Underperform$28.82M-1.76-36.21%―-24.44%-1012.80%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%SIBNATECOFIXZBHGMEDXTNTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SIBN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SIBNSi-Bone23.544.8626.02%
ATECAlphatec7.06-12.55-64.00%
OFIXOrthofix Medical Inc.6.61-7.68-53.74%
ZBHZimmer Biomet Holdings103.3215.1917.24%
GMEDGlobus Medical70.53-11.75-14.28%
XTNTXtant Medical Holdings Inc0.20-0.44-68.36%

SI-Bone Corporate Events

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

SI-BONE Announces Voluntary Recall of iFuse TORQ Implants

Negative
Sep 11, 2026

On August 21, 2026, SI-BONE initiated a voluntary recall of 98 iFuse TORQ implants whose tube packaging, manufactured between May 4 and May 15, 2026, failed to consistently meet sterile barrier criteria, creating a potential infection risk and possib...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026